Michelle Cecilia

Michelle Cecilia serves as a key procurement professional within the National Institute on Drug Abuse (NIDA), supporting the agency’s mission to advance scientific research on substance use disorders through strategic acquisition of specialized scientific and technical services. She manages a diverse portfolio of research-related contracts, primarily focused on laboratory instrumentation, pharmaceutical development, and clinical testing services that enable translational neuroscience and behavioral research. Her acquisitions directly support NIDA’s goal of bridging laboratory discoveries with clinical and public health applications, ensuring that funded research is equipped with cutting-edge tools and analytical capabilities. She maintains enduring partnerships with leading academic and research institutions, including The McLean Hospital Corporation, the University of Maryland Baltimore, the University of Miami, the University of Pittsburgh, and the Icahn School of Medicine at Mount Sinai. These relationships reflect a pattern of collaborative procurement with high-caliber research entities capable of delivering complex, multi-site clinical and preclinical studies, advanced neuroimaging protocols, and pharmacological testing services. Her contracting approach emphasizes scientific rigor, compliance with federal research standards, and long-term institutional engagement. Michelle’s procurement strategy prioritizes open competition, with 82.2% of awards issued under no set-aside provisions, reflecting the technical complexity and specialized expertise required for NIDA’s research initiatives. Nevertheless, she consistently allocates 17.8% of awards to total small business set-asides, demonstrating a deliberate commitment to fostering innovation from small, capable vendors. Her socioeconomic contracting patterns align with NIDA’s broader goals of expanding access to research capacity while maintaining scientific excellence. Her primary procurement focus lies in NAICS categories 334516 (analytical laboratory instruments), 325412 (pharmaceutical preparation manufacturing), and 541380 (testing laboratories), underscoring her technical expertise in procuring high-precision research equipment, drug formulation services, and validated analytical testing infrastructure critical to addiction science. She ensures acquisitions meet stringent regulatory and quality benchmarks for biomedical research applications.